A fluorescent nano vector for early diagnosis and enhanced Interleukin-33 therapy of thoracic aortic dissection. (February 2023)

• Record Type: Journal Article
• Authors: Ji, Chendong; Wang, Xue; Xue, Bingjie; Li, Shuolin; Li, Jianhao; Qiao, Bokang; Du, Jie; Yin, Meizhen; Wang, Yuan
• Is Part Of: Biomaterials. Volume 293(2023)
• Publication Date: 2023-02
• Subjects: Nano vector -- Interleukin-33 -- Perylenediimide -- Early diagnosis -- Thoracic aortic dissection; Biomedical materials -- Periodicals; Biocompatible Materials -- Periodicals; Biomatériaux -- Périodiques; 610.28
• DOI: 10.1016/j.biomaterials.2022.121958
• Languages: English
• ISSNs: 0142-9612

Abstract

Abstract: Thoracic aortic dissection (TAD) is the most devastating complication of vascular disease. The accuracy of the clinical diagnosis and treatment of TAD at the early stage is still limited. Herein, we report a nano-delivery strategy for early diagnosis and the first case of interleukin-33 (IL-33) based therapy for the effective intervention of TAD. A targeted fluorescent nano vector (FNV) is designed to co-assemble with IL-33, which protects IL-33 and prolongs its half-life. With specific targeting ability to the thoracic aorta, FNV can diagnose TAD at its early stage through fluorescent imaging. FNV@IL-33 nanocomplex presents better therapeutic effects on mice TAD progression compared with that of IL-33 alone by reducing smooth muscle apoptosis. Administration of FNV@IL-33 two weeks before onset, the development of TAD is greatly intervened. Our study provides a novel approach for early diagnosis and effective IL-33 therapy of TAD, which opens attractive opportunities for clinical prevention of cardiovascular diseases.